Navigation Links
The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
Date:10/8/2007

ching hospitals, the campus includes three state-of-the-art patient care facilities: the USC/Norris Comprehensive Cancer Center, USC University Hospital, and Doheny Eye Institute. USC faculty members staff these as well as many other hospitals in Southern California, including the nationally acclaimed Childrens Hospital Los Angeles. Because of its outstanding ranking and achievements in research and health care, USC's Health Sciences campus is a focal point for students, patients and scientists from around the world.

About the USC Stevens Institute for Innovation

The USC Stevens Institute for Innovation (http://stevens.usc.edu) is a university-wide resource in the Office of the Provost at the University of Southern California designed to harness and advance the creative thinking and breakthrough research from USC for societal impact. USC Stevens identifies, nurtures, protects, and transfers to the market the most exciting innovations from USC, and in turn, provides a central connection for industry seeking cutting-edge innovations in which to invest. Furthermore, USC Stevens develops the innovator as well as innovations, through educational programs, community-building events, and showcase opportunities. From the biosciences and technology to music and cinematic arts, USC Stevens connects faculty, students, and the business community to create an environment for stimulating and inspiring the process of innovation across all disciplines. USC Stevens was established through a generous $22M naming gift from USC alumnus and trustee Mark A. Stevens, a partner at the legendary Sequoia Capital venture capital firm, and his wife, Mary.

USC Media Contacts:

Elisa Wiefel,

USC Stevens Institute for Innovation

(213) 821-6063

wiefel@usc.edu

Sally Stewart

SA Stewart Communications for USC Stevens

(310) 394-8400


SOURCE University of Southern California
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UW-Stevens Point Professor Receives Patent Approval For New Technology
2. UW-Madison approves new research institute
3. Morgridge Institute for Research seeks first CEO
4. Waisman director leading early stages of the Wisconsin Institutes for Discovery
5. GE Healthcare partners with genomics institute
6. WARF, UW-Madison seek designer for the Wisconsin Institutes for Discovery
7. Leading cancer institute to install three TomoTherapy systems
8. Building commission approves Institutes for Discovery
9. Seven good reasons to approve the Institutes for Discovery
10. Morgridge gift enables phase one of Institute for Discovery
11. Flu institute a booster shot for Wisconsin biotech stature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has been ... an entity wholly owned by Mr. Yuen Kam, chairman ... acquired the outstanding shares (the "Shares") of  Excellent China ...
(Date:8/26/2015)... , ... August 26, 2015 , ... The 2015 Epigenomics ... adult stem cell technology start-up company Asymmetrex to share the first report ... of a new biomarker for counting adult tissue stem cells. , With a name ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from ... Per Share of $0.18, Full Year Revenue Guidance Raised from $14.6 Billion ... $14.9 Billion ... to $4.45 - $4.55, THOUSAND OAKS, Calif., Oct. 22 Amgen (Nasdaq:,AMGN) ...
... the leader in,automated proofreading solutions for the pharmaceutical ... pharmaceutical companies have selected Global,Vision to help them ... from,occurring in their packaging process. The integration of ... quality issues and,costs, along with speeding up product ...
... antagonist now approved in single-use ... ... US, Inc. today,announced that the U.S. Food and Drug Administration ... hydrochloride,injection) Premixed in 5% Dextrose. Discovered and developed by Astellas,Vaprisol, ...
Cached Biology Technology:Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 2Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 3Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 4Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 5Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 6Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 7Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 8Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 9Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 10Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 11Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 13Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 14Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 15Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 16Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 17Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 18Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 19Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 20Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 21Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 22Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 23Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 24Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... Microarrays designed for RNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... of our comprehensive DNA/RNA Aptamer Microarray Service. ... 2-OMe RNA Aptamer Microarray contains greater than ...
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... on-chip and LC Sciences can provide assistance ... available as part of our comprehensive DNA/RNA ...
Biology Products: